Study of the impacts of process changes of a pulp and paper mill on aerated stabilization basin (ASB) performance.

A laboratory scale (LS) and a field-based pilot plant (PP), designed to simulate aerobic stabilization basin (ASB) operation, were utilized to assess the potential impacts of changes in pulp and paper (P&P) mill operations on full-scale (FS) ASB performance. Two stages of investigation were conducted. The first was undertaken to determine the potential of pre-alum treatment of pulp mill wastewaters on ASB performance. The second investigation was conducted to assess ASB performance where wastewaters transitioned from being coagulated pulp and paper mill wastewaters to paper mill wastewaters only. Simulation ASB performance was assessed based on removals of BOD5, colour, UV@254 nm and nutrients [total phosphorus (TP) and nitrogen compounds (TN)]. Pre-alum treatment of pulp mill wastewaters with subsequent ASB treatment following mixing with paper mill wastewaters showed high percentage removals of BOD5. Despite low TP concentrations (≤0.05 mg/L) and low nutrient to BOD5 ratios of wastewaters in the LS-ASB trial, the high % BOD5 removal indicated recycling of nutrients from sludge [sourced from the FS-ASB]. Despite coagulation of pulp mill wastewater being performed using a very high alum dose (∼2000 mg/L) to remove colour and its precursors, colour formation remained high throughout the simulated ASB trials. Simulation of discontinuation of pulping indicated that colour would reduce rapidly to low levels in ASB wastewaters, but that TP and TN concentrations would persist for longer periods of time and decline slowly. Survey data of water qualities of the FS-ASB system obtained before, during and 2 years after discontinuation of pulping are presented.

Detection, characterization, and enrollment of donors of Ebola convalescent plasma in Sierra Leone.

BACKGROUND: Passive therapy with convalescent plasma provides an early opportunity to intervene in Ebola virus disease (EVD). Methods for field screening and selection of potential donors and quantifying plasma antibody are needed. STUDY DESIGN AND METHODS: Recombinant Ebola virus glycoprotein (EBOV GP) was formatted into immunoglobulin G-capture, competitive, and double-antigen bridging enzyme immunoassays (EIAs). EVD survivors in Freetown, Sierra Leone, were recruited as potential plasma donors and assessed locally using sera alone and/or paired sera and oral fluids (ORFs). Uninfected controls comprised unexposed Gambians and communities in Western Area, Sierra Leone. Antibody neutralization in selected sera was measured retrospectively in a pseudotype virus assay. RESULTS: A total of 115 potential donors were considered for enrollment: 110 plasma samples were concordantly reactive in the three EIAs; three were concordantly unreactive and two were reactive in two of three EIAs (98.2% agreement; 95% confidence interval [CI], 93.9%-99.8%). In 88 donors with paired ORF and plasma, G-capture EIA reactivity correlated well in the two analytes (R2 = 0.795). Plasma and ORF from 44 Gambians were unreactive. ORF samples from 338 of 339 unexposed Western Area community controls were unreactive (specificity, 99.7%; 95% CI, 98.4%-99.7%); ORF samples from 113 of 116 Kerry Town EVD survivors were reactive (sensitivity, 97.4%; 95% CI, 92.5%-99.5%). Strong reactivity in G-capture and/or competitive EIAs identified donors with high plasma EBOV GP antibody levels in the double-antigen bridging assay, correlating with high levels of neutralizing antibody. CONCLUSIONS: In-field testing can qualify convalescent donors for providing high-titer antibody.